ReviewTranslational cancer research2026
A narrative review of cinobufacini for endometrial cancer: mechanisms and therapeutic implications.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Advanced or recurrent endometrial cancer (EC) faces limited therapeutic options and frequent chemoresistance. Cinobufacini, a traditional Chinese medicine extract derived from the dried skin of Bufo bufo gargarizans Cantor, contains bufadienolides (including cinobufagin, bufalin, and cinobufotalin) as its core antitumor active constituents and exhibits broad-spectrum antitumor activity in multiple cancers. However, direct evidence in EC is limited. Its multitarget actions suggest potential applicability to EC. This study aimed to systematically elucidate the antitumor effects and molecular mechanisms of cinobufacini against EC and provide a theoretical basis for its clinical translation. Methods: A literature search was performed in PubMed, China National Knowledge Infrastructure (CNKI), and Elsevier using terms including "Cinobufacini", "cinobufagin", "toad venom", "anti cancer", "cancer", "endometrial cancer", and "molecular mechanism". Evidence on cinobufacini's anticancer mechanisms in other tumors was correlated with key molecular features of EC. Key Content and Findings: Cinobufacini's multitarget actions-inducing cell death and inhibiting proliferation-may counteract EC hallmarks such as phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), and hormone receptor pathway alterations, and could help overcome chemoresistance. However, direct preclinical and clinical data on EC are absent; rigorous Conclusions: Cinobufacini is a promising candidate for EC based on its established multitarget mechanisms in other cancers. This review offers a mechanistic rationale and framework for future EC-specific studies to enable clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.